KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2026)

Amneal Pharmaceuticals has reported Share-based Compensation over the past 8 years, most recently at $8.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 13.76% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $32.0 million, up 15.07%, while the annual FY2025 figure was $32.0 million, 15.07% up from the prior year.
  • Share-based Compensation for Q4 2025 was $8.2 million at Amneal Pharmaceuticals, roughly flat from $8.2 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $8.3 million in Q2 2025 and troughed at $5.3 million in Q1 2021.
  • A 5-year average of $7.3 million and a median of $7.6 million in 2021 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: soared 51.31% in 2022 and later dropped 23.71% in 2023.
  • Year by year, Share-based Compensation stood at $7.7 million in 2021, then rose by 1.15% to $7.8 million in 2022, then dropped by 23.71% to $6.0 million in 2023, then increased by 20.69% to $7.2 million in 2024, then grew by 13.76% to $8.2 million in 2025.
  • Business Quant data shows Share-based Compensation for AMRX at $8.2 million in Q4 2025, $8.2 million in Q3 2025, and $8.3 million in Q2 2025.